Company That Assembles The iPhone Hopes To Eventually Make Tesla Cars

Tesla Inc (NASDAQ: TSLA) is working hard to expand both Gigafactory Berlin and Texas to massively upscale its vehicle production capacity. But even as both factories ramp up, Tesla still has a hard time making enough vehicles to satisfy the high demand.

Tesla Inc (NASDAQ:TSLA) is working hard to expand both Gigafactory Berlin and Texas to massively upscale its vehicle production capacity. But even as both factories ramp up, Tesla still has a hard time making enough vehicles to satisfy the high demand.

As shared by The Verge, it seems Foxconn (OTC:HNHPF), maker of Apple Inc.’s (NASDAQ:AAPL) iPhone, hopes to someday help Tesla in its vehicle production goals. 

Foxconn’s chairman and CEO Liu Young-way said he wanted to eventually bring the company to a place where it can manufacture electric vehicles. The comment was made while unveiling two new EV prototypes, including the Model B crossover and Model V pickup truck. Foxconn created these as reference designs to attract companies that want to outsource the manufacturing of their EVs.

Foxconn said it is currently 40%-45% of the overall market share when it came to PCs and smartphones. The company was hopeful it could achieve the same type of penetration in the electric vehicle market.

Perhaps Apple’s own electric vehicle could be manufactured by the maker of its iPhones? 

Photo: Courtesy of Tesla

Total
0
Shares
Related Posts
Read More

Creative Media & Community Trust Form 13D Shows Mr. Negari Proposes To Acquire All Outstanding Shares Of The Co. For $8.88/Share In Cash And Noted He Intends To Evaluate All Of His Options And Take Action Should He Not Receive A Favorable Response

On April 17, 2023, Mr. Negari delivered a letter (the “Offer Letter”) to the Board of Directors of the Issuer (the “Board”) pursuant to which Mr. Negari proposed to acquire all of the outstanding

CMCT

Read More

Tenax Therapeutics Achieves Major Milestone As USPTO Grants Notice Of Allowance For U.S. Patent Application Covering Use Of Oral Levosimendan In Pulmonary Hypertension With Heart Failure With Preserved Ejection Fraction

Once granted, this patent will provide intellectual property protection until December 2040, and may qualify for additional U.S. patent term extension beyond 2040 There are currently no FDA approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030

TENX